Adamis Pharmaceuticals Co... (ADMP)
NASDAQ: ADMP
· Real-Time Price · USD
0.78
0.01 (1.50%)
At close: Sep 07, 2023, 9:59 PM
Adamis Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 9.06M | 6.95K | 1.45M | 2.15M | 1.51M | 39.85K | 1.15M | -1.16M | 759.96K | 4.01M | 4.11M |
Cost of Revenue | n/a | 361.39K | 1.79M | 2.48M | 1.65M | 689.18K | 1.46M | 2M | 1.24M | 3.87M | 3.64M |
Gross Profit | 9.06M | -354.45K | -335.07K | -331.11K | -141.9K | -649.33K | -309.07K | -3.15M | -475.64K | 140.67K | 466.58K |
Operating Income | -3.27M | -11.3M | -6.43M | -4.34M | -4.63M | -8.18M | -7.91M | -7.92M | -10.22M | -9.23M | -7.71M |
Interest Income | 13.84K | 703.00 | 11.00 | n/a | 298.12K | 16.17K | 4.15K | n/a | 1.93K | n/a | n/a |
Pretax Income | 348.2K | -7M | -9.01M | -3.4M | -4.27M | -8.34M | -10.19M | -7.81M | -5.17M | -9.31M | -15.38M |
Net Income | 348.2K | -8.57M | 71.7K | -3.4M | -4.4M | -8.4M | -10.35M | -8.77M | -12.36M | -9.31M | -15.38M |
Selling & General & Admin | 2.52M | 4.03M | 4.78M | 3.15M | 2.51M | 4.21M | 3.38M | 2.9M | 4.79M | 7.13M | 5.92M |
Research & Development | 418.52K | 376.96K | 1.31M | 859.85K | 1.98M | 3.32M | 4.22M | 2.2M | 4.62M | 2.23M | 2.26M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 5.01M | 7.89K | 16.2K |
Operating Expenses | 2.94M | 4.41M | 6.09M | 4.01M | 4.49M | 7.53M | 7.6M | 4.76M | 9.74M | 9.36M | 8.18M |
Interest Expense | -29.46K | 46.31K | 2.59M | n/a | 298.12K | n/a | n/a | n/a | 1.86K | 44.95K | 39.33K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 2.94M | 4.77M | 7.88M | 6.49M | 6.13M | 8.22M | 9.07M | 6.76M | 10.98M | 13.24M | 11.82M |
Income Tax Expense | n/a | 2.08M | -9.09M | 2K | 127.69K | -196.06K | -275.14K | 796.00 | 7.45M | 52.83K | 55.53K |
Shares Outstanding (Basic) | 7.07M | 2.57M | 2.18M | 2.14M | 2.14M | 2.14M | 2.14M | 2.13M | 2.13M | 2.13M | 1.85M |
Shares Outstanding (Diluted) | 7.07M | 2.57M | 2.18M | 2.14M | 2.14M | 2.14M | 2.14M | 2.13M | 2.13M | 2.13M | 1.85M |
EPS (Basic) | 0.05 | -3.34 | 0.03 | -1.59 | -2.05 | -3.92 | -4.84 | -4.12 | -5.81 | -4.38 | -8.32 |
EPS (Diluted) | 0.05 | -3.34 | 0.03 | -1.59 | -2.05 | -3.92 | -4.84 | -4.12 | -5.81 | -4.38 | -8.32 |
EBITDA | -3.27M | -4.21M | -3.84M | -4.66M | -3.93M | -8.05M | -8M | -7.55M | -10.22M | -8.54M | -7.05M |
EBIT | 318.74K | -13.45M | -6.43M | -3.65M | -3.97M | n/a | n/a | -7.92M | 5.04B | -9.27M | -15.3M |
Depreciation & Amortization | -39.59K | 87.35K | 2.58M | -320.16K | 697.1K | 368.36K | 344.15K | 363.91K | -253.93K | 678.6K | 647.16K |